Entering text into the input field will update the search result below

Alexion FY14 revenues up 44%

  • Alexion (NASDAQ:ALXN +3.8%) Q4 results: Revenues: $599.5M (+35.7%); COGS: $49.4M (-4.3%); R&D Expense: $129.1M (+50.5%); SG&A: $183.8M (+36.4%); Operating Income: $203.7M (+47.5%); Net Income: $153.3M (+906.8%); EPS: $0.76 (+860.0%).
  • FY2014 results: Revenues: $2,233.7M (+44.0%); COGS: $173.9M (-2.1%); R&D Expense: $513.8M (+62.0%); SG&A: $630.2M (+28.7%); Operating Income: $868.7M (+64.5%); Net Income: $656.9M (+159.7%); EPS: $3.26 (+156.7%); Quick Assets: $1961.6M (29.5%).
  • FY2015 Guidance: Revenue: $2.55B - $2.6B; Non-GAAP EPS: $5.60 - $5.80.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ALXN--
Alexion Pharmaceuticals, Inc.